Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for NRIX

Stock NameNurix Therapeutics Inc
TickerNRIX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS67080M1036

Show aggregate NRIX holdings

News associated with NRIX

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $28.87 Consensus Target Price from Brokerages
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the sixteen research firms that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price target […] - 2025-08-27 02:54:56
18,716 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Purchased by XTX Topco Ltd
XTX Topco Ltd purchased a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 18,716 shares of the company’s stock, valued at approximately $222,000. Other institutional investors and hedge funds have also […] - 2025-08-13 04:26:46
TD Asset Management Inc Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)
TD Asset Management Inc increased its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,420 shares of the company’s stock after purchasing an additional 3,186 […] - 2025-08-05 04:34:52
HC Wainwright Lowers Nurix Therapeutics (NASDAQ:NRIX) Price Target to $34.00
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its target price cut by equities research analysts at HC Wainwright from $36.00 to $34.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 179.84% from the stock’s previous […] - 2025-07-16 04:26:52
Analysts Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $30.18
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have received an average recommendation of “Moderate Buy” from the eighteen ratings firms that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12 month […] - 2025-07-08 03:10:44
Nurix: European Medicines Agency Grants Orphan Drug Designation To Bexobrutideg
(RTTNews) - Nurix Therapeutics (NRIX) announced that the European Medicines Agency has granted Orphan Drug Designation to bexobrutideg for the treatment of lymphoplasmacytic lymphoma. Bexobrutideg is an orally bioavailable, brain penetrant degrader of Brutons tyrosine kinase whic - 2025-07-07 08:41:27
Sumitomo Mitsui Trust Group Inc. Sells 33,252 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Sumitomo Mitsui Trust Group Inc. reduced its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 4.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 755,970 shares of the company’s stock after selling 33,252 shares during the […] - 2025-07-04 05:13:03
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $30.18
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eighteen research firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12-month target price […] - 2025-06-13 02:32:51
The Math Shows ESML Can Go To $48
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-05 07:20:56
ProShare Advisors LLC Acquires 7,261 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
ProShare Advisors LLC lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 45.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,132 shares of the company’s stock after buying an additional 7,261 shares during the period. […] - 2025-05-28 05:09:01
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $30.44
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nineteen ratings firms that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 1-year price […] - 2025-05-19 02:32:50
First Trust Advisors LP Acquires New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)
First Trust Advisors LP bought a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 135,903 shares of the company’s stock, valued at approximately $2,560,000. First Trust Advisors LP owned approximately […] - 2025-05-05 06:24:57
Invesco Ltd. Sells 361,360 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Invesco Ltd. lessened its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 87.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,980 shares of the company’s stock after selling 361,360 shares during the quarter. Invesco Ltd.’s holdings […] - 2025-05-02 05:06:53
Norges Bank Purchases Shares of 318,800 Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Norges Bank acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm acquired 318,800 shares of the company’s stock, valued at approximately $6,006,000. Other institutional investors also recently bought and sold shares of the company. NEOS Investment Management LLC purchased a new stake in […] - 2025-04-10 05:34:49
Vanguard Group Inc. Has $81.87 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Vanguard Group Inc. boosted its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.3% during the 4th quarter, HoldingsChannel reports. The fund owned 4,345,266 shares of the company’s stock after acquiring an additional 333,452 shares during the quarter. Vanguard Group Inc. owned about 0.06% of Nurix Therapeutics worth $81,865,000 as of its most […] - 2025-04-10 04:44:59
Peek Under The Hood: DFAC Has 28% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-04 08:47:40
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have received a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12-month price […] - 2025-03-27 04:38:49
US Bancorp DE Has $27,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)
US Bancorp DE raised its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 144.7% in the 4th quarter, HoldingsChannel reports. The fund owned 1,424 shares of the company’s stock after acquiring an additional 842 shares during the period. US Bancorp DE’s holdings in Nurix Therapeutics were worth $27,000 at the end of the […] - 2025-03-20 06:28:53
Bank of New York Mellon Corp Purchases 15,639 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Bank of New York Mellon Corp lifted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 190,905 shares of the company’s stock after buying an additional 15,639 shares during the […] - 2025-03-20 06:28:53
Leerink Partners Initiates Coverage on Nurix Therapeutics (NASDAQ:NRIX)
Leerink Partners began coverage on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a report published on Monday morning, MarketBeat Ratings reports. The firm issued a market perform rating and a $16.00 price target on the stock. Several other equities analysts also recently commented on the company. HC Wainwright increased their price target on […] - 2025-03-18 04:30:53
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $31.81
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1-year price objective […] - 2025-03-05 04:53:07
Rhumbline Advisers Acquires 12,315 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Rhumbline Advisers raised its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 13.5% during the fourth quarter, Holdings Channel reports. The firm owned 103,233 shares of the company’s stock after buying an additional 12,315 shares during the quarter. Rhumbline Advisers’ holdings in Nurix Therapeutics were worth $1,945,000 at the end of […] - 2025-03-04 06:10:55
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Expected to Rise, Morgan Stanley Analyst Says
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its price objective lifted by analysts at Morgan Stanley from $16.00 to $17.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price target indicates a potential downside of 8.55% from […] - 2025-02-05 04:44:53

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) NRIX holdings

DateNumber of NRIX Shares HeldBase Market Value of NRIX SharesLocal Market Value of NRIX SharesChange in NRIX Shares HeldChange in NRIX Base ValueCurrent Price per NRIX Share HeldPrevious Price per NRIX Share Held
2025-11-12 (Wednesday)51,761USD 629,931USD 629,931
2025-11-11 (Tuesday)51,628USD 663,936NRIX holding increased by 31493USD 663,9360USD 31,493 USD 12.86 USD 12.25
2025-11-10 (Monday)51,628NRIX holding increased by 133USD 632,443NRIX holding decreased by -1460USD 632,443133USD -1,460 USD 12.25 USD 12.31
2025-11-07 (Friday)51,495USD 633,903NRIX holding decreased by -10814USD 633,9030USD -10,814 USD 12.31 USD 12.52
2025-11-06 (Thursday)51,495NRIX holding increased by 133USD 644,717NRIX holding increased by 5003USD 644,717133USD 5,003 USD 12.52 USD 12.455
2025-11-05 (Wednesday)51,362USD 639,714NRIX holding increased by 10016USD 639,7140USD 10,016 USD 12.455 USD 12.26
2025-11-04 (Tuesday)51,362NRIX holding increased by 134USD 629,698NRIX holding decreased by -16799USD 629,698134USD -16,799 USD 12.26 USD 12.62
2025-11-03 (Monday)51,228USD 646,497NRIX holding decreased by -16393USD 646,4970USD -16,393 USD 12.62 USD 12.94
2025-10-31 (Friday)51,228USD 662,890NRIX holding increased by 8196USD 662,8900USD 8,196 USD 12.94 USD 12.78
2025-10-30 (Thursday)51,228NRIX holding increased by 670USD 654,694NRIX holding increased by 63165USD 654,694670USD 63,165 USD 12.78 USD 11.7
2025-10-29 (Wednesday)50,558NRIX holding increased by 268USD 591,529NRIX holding decreased by -6922USD 591,529268USD -6,922 USD 11.7 USD 11.9
2025-10-28 (Tuesday)50,290USD 598,451NRIX holding decreased by -4023USD 598,4510USD -4,023 USD 11.9 USD 11.98
2025-10-27 (Monday)50,290USD 602,474NRIX holding increased by 44758USD 602,4740USD 44,758 USD 11.98 USD 11.09
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NRIX by Blackrock for IE00BYXG2H39

Show aggregate share trades of NRIX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY13312.80012.200 12.260USD 1,631 14.31
2025-11-06BUY13312.88012.300 12.358USD 1,644 14.33
2025-11-04BUY13412.53012.160 12.197USD 1,634 14.35
2025-10-30BUY67013.23511.575 11.741USD 7,866 14.38
2025-10-29BUY26811.70012.010 11.979USD 3,210 14.39
2025-10-22SELL-53210.63011.700 11.593USD -6,167 14.48 Profit of 1,534 on sale
2025-10-20BUY26610.39010.470 10.462USD 2,783 14.52
2025-10-17BUY6649.84010.174 10.141USD 6,733 14.55
2025-10-15BUY1,05610.35010.430 10.422USD 11,006 14.57
2025-10-03BUY9389.3809.490 9.479USD 8,891 14.63
2025-10-02BUY1349.0809.690 9.629USD 1,290 14.66
2025-09-30BUY2689.2409.410 9.393USD 2,517 14.72
2025-09-26BUY2708.9309.066 9.052USD 2,444 14.79
2025-09-25BUY2708.3308.689 8.653USD 2,336 14.82
2025-09-24BUY18.7008.720 8.718USD 9 14.86
2025-09-18BUY1368.9709.060 9.051USD 1,231 14.89
2025-09-17BUY4088.5709.060 9.011USD 3,676 14.93
2025-08-20SELL-5369.5309.910 9.872USD -5,291 15.07 Profit of 2,784 on sale
2025-07-30BUY53211.88012.330 12.285USD 6,536 15.23
2025-07-17SELL-26612.09012.560 12.513USD -3,328 15.45 Profit of 781 on sale
2025-07-11SELL-1,06412.44012.900 12.854USD -13,677 15.53 Profit of 2,848 on sale
2025-07-07BUY39912.36012.745 12.706USD 5,070 15.61
2025-07-02BUY7,31512.44012.900 12.854USD 94,027 15.66
2025-06-20BUY2,32411.49011.880 11.841USD 27,518 15.68
2025-06-11BUY25212.63013.090 13.044USD 3,287 15.89
2025-06-10BUY25212.79013.035 13.010USD 3,279 15.91
2025-06-04SELL-12612.16012.390 12.367USD -1,558 16.02 Profit of 460 on sale
2025-04-23BUY12611.61012.380 12.303USD 1,550 17.72
2025-04-10SELL-1,0088.8109.930 9.818USD -9,897 18.50 Profit of 8,756 on sale
2025-04-08SELL-1269.26010.390 10.277USD -1,295 18.71 Profit of 1,063 on sale
2025-04-07SELL-1269.7209.910 9.891USD -1,246 18.82 Profit of 1,125 on sale
2025-04-04SELL-6309.69010.520 10.437USD -6,575 18.93 Profit of 5,347 on sale
2025-04-01BUY52010.47011.890 11.748USD 6,109 19.12
2025-03-31SELL-37811.88012.030 12.015USD -4,542 19.21 Profit of 2,718 on sale
2025-03-21BUY4,10612.99013.670 13.602USD 55,850 19.72
2025-03-14SELL-1,80813.59013.640 13.635USD -24,652 20.14 Profit of 11,753 on sale
2025-03-07SELL-22613.86014.290 14.247USD -3,220 20.61 Profit of 1,439 on sale
2025-03-04SELL-11314.26014.580 14.548USD -1,644 20.92 Profit of 720 on sale
2025-02-25BUY22616.47016.980 16.929USD 3,826 21.38
2025-02-19SELL-11217.35017.405 17.400USD -1,949 21.70 Profit of 481 on sale
2025-02-13BUY33617.57017.850 17.822USD 5,988 22.04
2025-02-12BUY11217.31017.350 17.346USD 1,943 22.14
2025-02-11BUY44817.12018.180 18.074USD 8,097 22.24
2024-12-30SELL-56518.64019.085 19.040USD -10,758 23.58 Profit of 2,567 on sale
2024-11-18SELL-1,66521.79022.710 22.618USD -37,659 25.70 Profit of 5,123 on sale
2024-11-08SELL-11127.34027.750 27.709USD -3,076 25.48 Loss of -247 on sale
2024-10-21SELL-11125.48025.880 25.840USD -2,868 0.00 Loss of -2,868 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NRIX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1976,8690337,08922.8%
2025-09-18115,92697470,43424.6%
2025-09-17126,6710672,96118.8%
2025-09-16103,8500416,87924.9%
2025-09-15262,1910512,07451.2%
2025-09-12144,9620456,36631.8%
2025-09-11113,1840213,49353.0%
2025-09-10110,091853183,50260.0%
2025-09-09136,7630288,47047.4%
2025-09-08123,9465228,58854.2%
2025-09-05123,9370238,53852.0%
2025-09-0472,9400129,91856.1%
2025-09-03181,0680299,30660.5%
2025-09-0276,5100353,68721.6%
2025-08-29203,27842356,57357.0%
2025-08-2855,2460151,08436.6%
2025-08-2771,6173,905118,66060.4%
2025-08-2686,48920165,94752.1%
2025-08-2541,3940100,22041.3%
2025-08-2265,6450165,09339.8%
2025-08-2158,041166177,37732.7%
2025-08-2067,9970191,75435.5%
2025-08-1997,083865296,24032.8%
2025-08-1880,47101,066,5277.5%
2025-08-1559,9120124,04048.3%
2025-08-1479,2250116,84467.8%
2025-08-1397,4330177,94354.8%
2025-08-1273,47477151,97648.3%
2025-08-11103,91753233,58944.5%
2025-08-0885,6990162,58652.7%
2025-08-0770,5880116,88960.4%
2025-08-06215,45841268,13680.4%
2025-08-0578,0950149,09052.4%
2025-08-0470,1414117,12159.9%
2025-08-0199,67485116,92485.2%
2025-07-31218,9450624,75535.0%
2025-07-30162,5854,925194,36783.6%
2025-07-29180,029442376,03447.9%
2025-07-28251,7550464,58554.2%
2025-07-2578,11526128,30660.9%
2025-07-2489,575429240,85737.2%
2025-07-2379,3730288,37827.5%
2025-07-22102,1930188,09354.3%
2025-07-2181,2040127,39163.7%
2025-07-18156,5821,615261,96359.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.